Figure 2. (A) Sézary syndrome patient before treatment

Slides:

Advertisements

Similar presentations

From: An open day in the metric space

Advertisements

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Fig. 1 Graphical representation

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

Error bars represent the mean (s.e.).

Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p

pSS: primary SS; Scl: scleroderma.

Figure 1. Selection of papers.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Fig. 1. Geographic locations of Shenzhen and Dongguan

Figure 1 (A) Chest computed tomography scans of the patient

Figure 2. Kaplan–Meier survival analysis in patients

Fig 1 Respiratory support escalation strategies for study patients

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

From: Where do we go from here

From: A European Disease

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Figure 1. Single-Tree Model and BART Fits to Simulated Data.

Figure 1 Study flowchart.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1 Flow of data processing

Figure 1. Examples of e-cigarette discussions in social media

From: Estimating the Location of World Wheat Price Discovery

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 1: Logistic regression showing association of prescribing provider and patient panel characteristics with occurrence of a hospitalization or ED.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

From: Consumer Bankruptcy, Bank Mergers, and Information *

Figure 2 Comparison of pregnancy outcomes between true NC-FET and modified NC-FET. Odds ratio (OR) adjusted for clinical pregnancy (OR 0.90, 95% CI 0.73–1.12)

Figure 3. Proposed algorithm of treatment for patients with a diagnosis of PI [prepouch ileitis]. From: Prepouch Ileitis After Ileal Pouch-anal Anastomosis:

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Take home figure The protective role of CNP/NPR-B/NPRC.

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient selection

Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Figure 1 Patient selection.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Presentation transcript:

Figure 2. (A) Sézary syndrome patient before treatment Figure 2. (A) Sézary syndrome patient before treatment. (B) Sézary syndrome patient after three courses of therapy. From: Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome) Ann Oncol. 2014;25(9):1807-1812. doi:10.1093/annonc/mdu231 Ann Oncol | © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figure 1. (A) Mycosis fungoides patient before treatment Figure 1. (A) Mycosis fungoides patient before treatment. (B) Mycosis fungoides patient after 10 weeks of treatment. From: Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome) Ann Oncol. 2014;25(9):1807-1812. doi:10.1093/annonc/mdu231 Ann Oncol | © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.